Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Non Operating Income (2019 - 2025)

Historic Non Operating Income for aTYR PHARMA (ATYR) over the last 6 years, with Q3 2025 value amounting to $999000.0.

  • aTYR PHARMA's Non Operating Income rose 1326.53% to $999000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 1684.76%. This contributed to the annual value of $3.9 million for FY2024, which is 1393.19% down from last year.
  • Per aTYR PHARMA's latest filing, its Non Operating Income stood at $999000.0 for Q3 2025, which was up 1326.53% from $781000.0 recorded in Q2 2025.
  • Over the past 5 years, aTYR PHARMA's Non Operating Income peaked at $1.3 million during Q3 2023, and registered a low of $224000.0 during Q1 2022.
  • For the 4-year period, aTYR PHARMA's Non Operating Income averaged around $856000.0, with its median value being $887000.0 (2024).
  • In the last 5 years, aTYR PHARMA's Non Operating Income soared by 41538.46% in 2023 and then crashed by 3071.48% in 2024.
  • Quarter analysis of 4 years shows aTYR PHARMA's Non Operating Income stood at $427000.0 in 2022, then surged by 180.56% to $1.2 million in 2023, then fell by 28.88% to $852000.0 in 2024, then grew by 17.25% to $999000.0 in 2025.
  • Its Non Operating Income stands at $999000.0 for Q3 2025, versus $781000.0 for Q2 2025 and $892000.0 for Q1 2025.